Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 6Active not recruiting 6Recruiting 5Terminated 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 6Ovarian Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Neoplasms × dostarlimab × Clear all
NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Tesaro, Inc.

Phase 1 Completed
60 enrolled 91 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT06926673 2025-07-03

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

GlaxoSmithKline

Phase 2 Completed
62 enrolled 36 charts
Tumor-Agnostic

Neoplasms

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

GlaxoSmithKline

Phase 2 Completed
175 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

GlaxoSmithKline

Phase 1 Completed
829 enrolled 100 charts
Tumor-Agnostic

Neoplasms

NCT03250832 2024-04-11

CITRINO

Tesaro, Inc.

Phase 1 Completed
111 enrolled 48 charts
GastrointestinalGynecologicThoracic

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Tesaro, Inc.

Phase 2 Completed
53 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡